256 related articles for article (PubMed ID: 34759925)
1. Depletion of Human Papilloma Virus E6- and E7-Oncoprotein-Specific T-Cell Responses in Women Living With HIV.
Mbuya W; Held K; Mcharo RD; Haule A; Mhizde J; Mnkai J; Mahenge A; Mwakatima M; Sembo M; Mwalongo W; Agrea P; Hoelscher M; Maboko L; Saathoff E; Geisenberger O; Rwegoshora F; Torres L; Koup RA; Kroidl A; Chachage M; Geldmacher C
Front Immunol; 2021; 12():742861. PubMed ID: 34759925
[TBL] [Abstract][Full Text] [Related]
2. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
3. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
[TBL] [Abstract][Full Text] [Related]
4. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
6. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
7. Human Papillomavirus (HPV) 16/18 E6 Oncoprotein Expression in Infections with Single and Multiple Genotypes.
Wu Z; Li TY; Jiang M; Yu L; Zhao J; Wang H; Zhang X; Chen W; Qiao Y
Cancer Prev Res (Phila); 2019 Feb; 12(2):95-102. PubMed ID: 30606718
[TBL] [Abstract][Full Text] [Related]
8. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
[TBL] [Abstract][Full Text] [Related]
9. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
10. Immunoexpression of HPV 16/18 E6 and E7 oncoproteins in high-grade cervical squamous intraepithelial lesions in HIV-positive women.
Rodrigues LC; Speck NM; Focchi GR; Schimidt MA; Marques RM; Ribalta JC
Genet Mol Res; 2016 Feb; 15(1):. PubMed ID: 26909984
[TBL] [Abstract][Full Text] [Related]
11. Eight-type human papillomavirus E6/E7 oncoprotein detection as a novel and promising triage strategy for managing HPV-positive women.
Rezhake R; Hu SY; Zhao S; Xu XQ; Zhao XL; Zhang L; Wang Y; Zhang X; Pan QJ; Qiao YL; Zhao FH
Int J Cancer; 2019 Jan; 144(1):34-42. PubMed ID: 29943809
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6.
de Jong A; van Poelgeest MI; van der Hulst JM; Drijfhout JW; Fleuren GJ; Melief CJ; Kenter G; Offringa R; van der Burg SH
Cancer Res; 2004 Aug; 64(15):5449-55. PubMed ID: 15289354
[TBL] [Abstract][Full Text] [Related]
13. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
15. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
16. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.
Beachler DC; Viscidi R; Sugar EA; Minkoff H; Strickler HD; Cranston RD; Wiley DJ; Jacobson LP; Weber KM; Margolick JB; Reddy S; Gillison ML; D'Souza G
Sex Transm Dis; 2015 Feb; 42(2):93-7. PubMed ID: 25585068
[TBL] [Abstract][Full Text] [Related]
17. HPV-16 E7-Specific Cellular Immune Response in Women With Cervical Intraepithelial Lesion Contributes to Viral Clearance: A Cross-Sectional and Longitudinal Clinical Study.
Zhang L; Shi X; Zhang Q; Mao Z; Shi X; Zhou J; Jian A; Zhu R; Jiang S; Lu W
Front Immunol; 2021; 12():768144. PubMed ID: 35095843
[TBL] [Abstract][Full Text] [Related]
18. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus 16 (HPV16) and HPV52 E6-specific immunity in HIV-infected adults on combination antiretroviral therapy.
Leng CY; Low HC; Chua LL; Chong ML; Sulaiman H; Azwa I; Roberts JM; Kamarulzaman A; Rajasuriar R; Woo YL
HIV Med; 2017 May; 18(5):321-331. PubMed ID: 27649852
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a multiplex immunoassay for the simultaneous quantification of type-specific IgG antibodies to E6/E7 oncoproteins of HPV16 and HPV18.
Layman H; Rickert KW; Wilson S; Aksyuk AA; Dunty JM; Natrakul D; Swaminathan N; DelNagro CJ
PLoS One; 2020; 15(3):e0229672. PubMed ID: 32214362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
